Clinical application of an antibiotic's pharmacokinetic/pharmacodynamic (PK/PD) properties may improve the outcome of severe infections. No data are available on the use of linezolid (LNZ) continuous infusion in critically ill obese patients affected by ventilator-associated pneumonia (VAP).
De Pascale, G., Fortuna, S., Tumbarello, M., Cutuli, S., Vallecoccia, M. S., Spanu Pennestri, T., Bello, G., Montini, L., Pennisi, M. A., Navarra, P., Antonelli, M., Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration, <<INTENSIVE CARE MEDICINE>>, 2015; 41 (1): 103-110. [doi:10.1007/s00134-014-3550-y] [http://hdl.handle.net/10807/72198]
Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration
De Pascale, Gennaro;Tumbarello, Mario;Vallecoccia, Maria Sole;Spanu Pennestri, Teresa;Bello, Giuseppe;Montini, Luca;Pennisi, Mariano Alberto;Navarra, Pierluigi;Antonelli, Massimo
2015
Abstract
Clinical application of an antibiotic's pharmacokinetic/pharmacodynamic (PK/PD) properties may improve the outcome of severe infections. No data are available on the use of linezolid (LNZ) continuous infusion in critically ill obese patients affected by ventilator-associated pneumonia (VAP).
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
